Impact of Pharmaceutical Care on Quality of Life in Breast Cancer Patients: A Randomized Controlled Trial
Article Sidebar
Main Article Content
Abstract
Objective: To evaluate the impact of pharmaceutical care on quality of life and adverse events in breast cancer patients receiving chemotherapy. Methods: This study was a randomized controlled trial with parallel design in newly diagnosed breast cancer patients treated with chemotherapy at Kamphaeng Phet hospital. The study compared patients receiving pharmaceutical care with the identification and resolution of drug-therapy problems by pharmacists before attending the doctors with those receiving standard care of the hospitals. The study allocated participants using block randomization. Primary outcome was quality of life which was assessed using Thai version of the Functional Assessment of Cancer Therapy-Breast (FACT-B). Secondary outcome was adverse drug reactions evaluated according to the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE). The study followed the patients until the 3rd cycle of their chemotherapy. Results: Fifty- four patients participated in the study with an average age of 53.3 years, 27 received pharmaceutical care and another 27 received standard care. After the 3rd cycle of chemotherapy, the mean overall quality of life of patients who received pharmaceutical care before attending the doctor was higher than that of those in standard care group (132.8+7.6 vs 119.2+14.3, P<0.001). Moreover, those receiving pharmaceutical care before attending the doctor reported having less nausea and anorexia compared with those in the standard care (0.0% vs 29.6%, P=0.004; and 7.4% vs 37.0%, P=0.009, respectively). Conclusion: Pharmaceutical care before attending the doctor has showed to improve patients’ quality of life and reduce adverse events associated with chemotherapy. This service should therefore be promoted to breast cancer patient receiving chemotherapy.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Ministry of Public Health. Health data center 2018 [online]. 2018 [cited Oct 27, 2018]. Available from: hdcservice.moph.go.th/hdc/reports/report.php?source=formated/ncd.php&cat_id=59acae7a68f02c8e2c0cb88dfc6df3b3&id=825c7fbfdbde936cf821a9b16dc4189b.
3. Strategy and Planning Division. Public health statistics A.D.2016 [online]. 2018 [cited Feb 25, 2018]. Available from: bps.moph.go.th/new_bps/site s/default /files/health_strategy2559.pdf.
4. Sookprasert A. A step by step practical guide before giving chemotherapy [online]. 2011 [cited Feb 25, 2018]. Available from: thaihp.org/index2.php?option =showfile&tbl=home&id=972.
5. Bastani P, Ahmad Kiadaliri A. Health-related quality of life after chemotherapy cycle in breast cancer in Iran. Med Oncol. 2011; 28 Suppl 1:S70-4.
6. Park H, Yoon HG. Menopausal symptoms, sexual function, depression, and quality of life in Korean patients with breast cancer receiving chemotherapy. Support Care Cancer. 2013; 21: 2499-507.
7. Montakantikul P. Systematic pharmaceutical care. In: Ningsanon T editor. Essential tools for pharma ceutical care. Bangkok: Prachachon; 2015. p. 9-32.
8. Subongkot S, Srisawat S, Pratheepawanit Johns N, Sookprasert A. Outcome of chemotherapy counse- ling in oncology patients by pharmacist. Isan Journal of Pharmaceutical Sciences. 2019; 5: 34-45.
9. Chuepool Y. Effects of pharmaceutical care on quality of life in lung cancer patients treated with chemo- therapy at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai Province [master thesis]. Chiang Mai: Chiang Mai University; 2005.
10. Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, et al. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer. 2012; 20: 2669-77.
11. Kawaguchi T, Iwase S, Koinuma M, Onodera Y, Takeuchi H, Umeda M, et al. Determinants affecting quality of life: implications for pharmacist counseling for patients with breast cancer in Japan. Biol Pharm Bull. 2012; 35: 59-64.
12. Cushnie B, Hatsarin S. Effect of pharmaceutical care among breast cancer patients undergoing chemotherapy at Udonthani Regional Center, Thailand. Thai Cancer Journal 2011; 31: 93-105.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
14. Eng J. Sample size estimation: how many indivi- duals should be studied? Radiology. 2003; 227: 309-13.
15. Collins KMT, Onwuegbuzie AJ, Jiao QG. A mixed methods investigation of mixed methods sampling designs in social and health science research. J Mix Methods Res 2007; 1: 267-94.
16. Kaewkungawal J, Singhasivanon P. Sample size in clinical research. In: Pitisuttithum P, editor. Textbook of clinical research. Bangkok: Amarin Printing; 2014. p.134-5.
17. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-86.
18. Sirilerttrakul S, Jirajarus M, Ratanatharathon V, Nuch Charoenkul, Sirachainan E, Nilchaikovit T. Quality of life measurement of Functional Assess ment of Cancer Therapy (FACT) translated into Thai In breast cancer, colon cancer and lung cancer patients. Thai Journal of Nursing Research. 2000; 4: 61-76.
19. Ratanatharathorn V, Sirilerttrakul S, Jirajarus M, Silpakit C, Maneechavakajorn J, Sailamai P, et al. Quality of life, Functional Assessment of Cancer Therapy-General. J Med Assoc Thai 2001; 84: 1430- 42.
20. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [on line]. 2009 [cited Mar 3, 2015]; Available from: evs.nc I.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Qu ickReference_8.5x 11.pdf.
21. Pratheepawanit NJ. Introduction. In: Pratheepawanit NJ. Health-related quality of life: evaluation and appli cation. Khon Kaen: Khon Kaen University printing; 2009. p. 9-12.
22. Cella DF. Quality of life: concepts and definition. J Pain Symptom Manage. 1994; 9: 186-92.
23. Petpichetchian W. Best nursing practice in cancer care. Songkhla: Orang media; 2011.
24. Jewpattanakul Y, Phuphaibul R, Loveland-Cherry C, Nityasuddhi D, Suwonnaroop N. Factors influencing well-being among families with adolescents living in and around Bangkok, Thailand. Pacific Rim Interna tional Journal of Nursing Research. 2010; 14: 235-248.
25. Pratheepawanit JN, Weerapreeyakul T, Vashirodom D, Putthisavat V, Wiangnon S, Limwattannanom C. Evaluation of the impact of treatments on quality of life of breast cancer patients and quality of life database in Khon Kaen province [research report]. Khon Kaen: Khonkaen University; 2009.
26. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically im portant difference. Control Clin Trials 1989; 10: 407-15.
27. Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. Minimal clinically important difference (MC ID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol 2014; 67: 811-20.
28. Ob-oun T, Kopol J, Phosahut P, Thirasirawate S, Chisong C, Phumart P, et al. Adverse drug reaction monitoring and counseling in oncologic patients at Mahasarakham Hospital Khon Kaen [online]. 2012 [cited Dec 11, 2017]. Available from: pharm.kku.ac.th /isan-journal/journal/volumn8-no1/4annual/017-MSU _Pages_135-143.pdf.